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It is very gratifying to see that alkaptonuria has now
finally caught up with most of the other metabolic dis-
orders formerly called “inborn errors of metabolism.”
Thanks to these recent advances we have a much better
understanding of the molecular basis and mutational
events that produce this well-known prototypic meta-
bolic disorder. Alkaptonuria is characterized by the pass-
ing of urine that blackens with the addition of alkali,
by a gradual development of an intensive connective-
tissue melanin-like pigmentation (ochronosis), and, with
advancing years, by a type of arthritis that resembles
osteoarthritis in its distribution but that also includes
acute inflammatory episodes (La Du 1995).
The Spanish investigators responsible for the very in-
formative and landmark article appearing in this issue
of the Journal (Beltran-Valero de Bernabe et al. 1998)
previously reported the cloning of the AKU gene (Fer-
nandez-Canon et al. 1996), and they also published a
detailed description of the human gene coding for hom-
ogentisic acid oxidase (HGO) (Granadino et al. 1997).
A complete deficiency of this enzyme is responsible for
an accumulation of 2,5-dihydroxyphenyl acetic acid
(HGA), an intermediary compound arising during the
metabolism of the aromatic amino acids phenylalanine
and tyrosine. Practically all of this was predicted by the
English physician Sir Archibald Garrod, in the early
1900s, in his Croonian lectures (Garrod 1908). His con-
ception of inherited metabolic diseases was far ahead of
his time, and his correct hypothesis that defective genes
are responsible for particular enzymatic deficiency dis-
eases was a remarkable achievement, especially consid-
ering how little was known about enzymes, human ge-
netics, and intermediary metabolism, at that time.
The article by Beltran-Valero de Bernabe et al. (1998)
is a comprehensive study of the genetic defects in 14
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unrelated representative alkaptonuric subjects from six
European countries, Algeria, and Turkey. Point muta-
tions believed to be responsible for the alkaptonuric phe-
notype were identified in 11 of the 14 exons, and several
intronic defects also were found to be associated with
this hereditary disorder. For three disease chromosomes
from alkaptonuric individuals, Beltran-Valero de Ber-
nabe et al. were unable to identify the nature of the
defect. Nevertheless, it is obvious that a wide variety of
molecular defects can lead to the common phenotype
alkaptonuria. Presumably, most sporadic patients have
a combination of two rare, different alleles and are not
homozygous for one particular HGO mutation. Tracing
of the different allelic variants associated with alkap-
tonuria will be aided by the careful characterization of
haplotypes, on the basis of several new polymorphic
markers and repetitive sequences in the gene that also
are identified by Beltran-Valero de Bernabe et al.
Another laboratory, studying alkaptonuria in the Slo-
vak regions, which have a relatively high incidence of
this disorder, independently cloned the human HGO
gene and found a frameshift mutation at position
454–457 and a missense mutation, G481A, in two of
the alkaptonuric families of that area (Gehrig et al.
1996). Further experience will indicate whether a few
mutations predominate among the extended alkapton-
uric families in that rather isolated region. The reported
higher incidence of alkaptonuria in the Dominican Re-
public, which at one time appeared to support the pos-
sibility that a dominant type of alkaptonuria existed,
probably will be explained by the frequency of a single
or, more likely, of a few abnormal alleles circulating
within a limited population, owing to consanguinity and
the intermarriage customs of that ethnic group.
Attempts to treat alkaptonuria by use of genetic en-
gineering to replace the missing enzyme no doubt will
be made soon. This disorder also has the attractive fea-
ture that any significant correction of the missing en-
zymatic function can be easily detected and monitored
simply by following the degree of reduction in the
amount of HGA excretion in the urine each day, pro-
vided that the patient has been on a fixed dietary-protein
intake. However, genetic treatment of this disorder
should proceed with due caution. Adult alkaptonurics
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Figure 1 Scheme of tyrosine metabolism. A hereditary defect in
HGO is responsible for alkaptonuria, a disease that is readily diag-
nosed through elevated levels of homogentisic acid in the urine. Aware-
ness of this entire biochemical pathway will be needed in order to
design gene therapies for alkaptonuria, to avoid creation of novel
metabolic defects in the subjects.
on a regular diet produce ∼5–7 g of HGA/d and even
more than that on a diet higher in protein. Most of this
product is efficiently eliminated in the urine, because
HGA is actively secreted by the kidneys. Renal secretion
of HGA remains the important line of defense for the
alkaptonuric: it reduces the accumulation of HGA in
alkaptonuric tissues and thereby slows the development
of ochronosis and arthritis (La Du 1995).
Providing the missing HGO to alkaptonurics should
produce large amounts of the expected product maley-
lacetoacetic acid (MAA). This acid normally is then con-
verted, by the next enzyme, an isomerase, to fumary-
lacetoactetic acid (FAA) (fig. 1), and the latter is split,
by a hydrolase, into fumarate and acetoacetate (fig. 1).
In normal liver, these sequential steps proceed very
smoothly and efficiently, without the accumulation of
MAA or FAA. Also, in normal liver, most of the HGA
metabolism takes place in the soluble fraction of the
hepatocytes, the fraction which also contains the sub-
sequent enzymes. Interestingly, alkaptonuric liver also
has normal levels of the later enzymes in the pathway,
even though these enzymes presumably have never been
called on to metabolize any substrate (La Du et al. 1958).
From what we know today, localizing the recombinant
HGO to its normal location in liver cells would seem to
be the best strategy.
But what might be the consequences if recombinant
HGO were localized in liver or other tissues, at some
distance from the isomerase and the hydrolase? MAA
and/or FAA then could accumulate in appreciable
amounts. The hydrolase is rather widely distributed in
tissues, but little is known about the tissue distribution
of the isomerase. Maleic acid has been employed ex-
perimentally in animals, to deplete the liver of glutathi-
one and other sulfhydryl compounds. The severe liver
cirrhosis, renal Fanconi syndrome, and peripheral neu-
ropathy that rapidly develop in young babies with the
hepatorenal type of hereditary tyrosinemia, owing to
deficiencies of the FAA hydrolase, are life threatening
features of that deficiency (Mitchell et al. 1995). Mice
deficient in FAA hydrolase also show extensive liver pa-
thology, presumably as a result of the accumulation of
these later tyrosine metabolites. In any case, model an-
imal systems (either those representing known sponta-
neous hereditary deficiencies of HGO) (Montagutelli et
al. 1994) or appropriate “knockout” animals with cre-
ated deficiencies of this enzyme need to be tested before
human trials are undertaken. The consequences of al-
kaptonuria are well known and established. We all hope
that some, perhaps all, of these adverse effects can be
prevented by new molecular therapeutic approaches.
However, trading alkaptonuric problems for, quite pos-
sibly, even-more-serious metabolic disturbances, because
of the pronounced toxicity of the later tyrosine metab-
olites, is not an acceptable alternative.
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